BACKGROUND: Chronic inflammation has been proposed as a risk factor for ovarian cancer. Some data suggest that anti-inflammatory medications may be protective against ovarian cancer; however, results have been inconsistent. METHODS: We evaluated the risk of epithelial ovarian cancer with regular use of NSAIDs prospectively in the NIH-AARP Diet and Health Study, using Cox proportional hazard models. We also examined the risk of common subtypes of epithelial ovarian cancer (serous, mucinous, endometrioid, clear cell, and other epithelial) with regular use of NSAIDs. In addition, we performed meta-analyses summarizing the risk of ovarian cancer with "regular use" of NSAIDs in previously published studies. RESULTS: We did not observe a significant association between regular use of NSAIDs with ovarian cancer risk in the AARP cohort (aspirin: RR 1.06, 95 % CI 0.87-1.29; non-aspirin NSAIDs: RR 0.93, 95 % CI 0.74-1.15); however, summary estimates from prospective cohort studies demonstrated that use of non-aspirin NSAIDs may reduce the risk of ovarian cancer (RR 0.88, 95 % CI 0.77-1.01). Although not significant, we found that mucinous tumors were inversely associated with non-aspirin NSAID use (RR 0.69, 95 % CI 0.23-2.10) in the AARP cohort, which was supported by the meta-analysis (RR 0.69, CI 0.50-0.94.) CONCLUSION: Although results from the NIH-AARP cohort study were not statistically significant, our meta-analysis suggests that non-aspirin NSAIDs may be protective against ovarian cancer. Additional analyses, focusing on dose, duration, and frequency of NSAID use and accounting for ovarian cancer heterogeneity are necessary to further elucidate the association between NSAID use and ovarian cancer risk.
BACKGROUND:Chronic inflammation has been proposed as a risk factor for ovarian cancer. Some data suggest that anti-inflammatory medications may be protective against ovarian cancer; however, results have been inconsistent. METHODS: We evaluated the risk of epithelial ovarian cancer with regular use of NSAIDs prospectively in the NIH-AARP Diet and Health Study, using Cox proportional hazard models. We also examined the risk of common subtypes of epithelial ovarian cancer (serous, mucinous, endometrioid, clear cell, and other epithelial) with regular use of NSAIDs. In addition, we performed meta-analyses summarizing the risk of ovarian cancer with "regular use" of NSAIDs in previously published studies. RESULTS: We did not observe a significant association between regular use of NSAIDs with ovarian cancer risk in the AARP cohort (aspirin: RR 1.06, 95 % CI 0.87-1.29; non-aspirin NSAIDs: RR 0.93, 95 % CI 0.74-1.15); however, summary estimates from prospective cohort studies demonstrated that use of non-aspirin NSAIDs may reduce the risk of ovarian cancer (RR 0.88, 95 % CI 0.77-1.01). Although not significant, we found that mucinous tumors were inversely associated with non-aspirin NSAID use (RR 0.69, 95 % CI 0.23-2.10) in the AARP cohort, which was supported by the meta-analysis (RR 0.69, CI 0.50-0.94.) CONCLUSION: Although results from the NIH-AARP cohort study were not statistically significant, our meta-analysis suggests that non-aspirin NSAIDs may be protective against ovarian cancer. Additional analyses, focusing on dose, duration, and frequency of NSAID use and accounting for ovarian cancer heterogeneity are necessary to further elucidate the association between NSAID use and ovarian cancer risk.
Authors: Alaa Rostom; Catherine Dubé; Gabriela Lewin; Alexander Tsertsvadze; Nicholas Barrowman; Catherine Code; Margaret Sampson; David Moher Journal: Ann Intern Med Date: 2007-03-06 Impact factor: 25.391
Authors: James V Lacey; Mark E Sherman; Patricia Hartge; Arthur Schatzkin; Catherine Schairer Journal: Int J Cancer Date: 2004-01-10 Impact factor: 7.396
Authors: Simone P Pinheiro; Shelley S Tworoger; Daniel W Cramer; Bernard A Rosner; Susan E Hankinson Journal: Am J Epidemiol Date: 2009-04-02 Impact factor: 4.897
Authors: H T Sørensen; S Friis; B Nørgård; L Mellemkjaer; W J Blot; J K McLaughlin; A Ekbom; J A Baron Journal: Br J Cancer Date: 2003-06-02 Impact factor: 7.640
Authors: Mollie E Barnard; Elizabeth M Poole; Gary C Curhan; A Heather Eliassen; Bernard A Rosner; Kathryn L Terry; Shelley S Tworoger Journal: JAMA Oncol Date: 2018-12-01 Impact factor: 31.777
Authors: Britton Trabert; Elizabeth M Poole; Emily White; Kala Visvanathan; Hans-Olov Adami; Garnet L Anderson; Theodore M Brasky; Louise A Brinton; Renee T Fortner; Mia Gaudet; Patricia Hartge; Judith Hoffman-Bolton; Michael Jones; James V Lacey; Susanna C Larsson; Gerardo G Mackenzie; Leo J Schouten; Dale P Sandler; Katie O'Brien; Alpa V Patel; Ulrike Peters; Anna Prizment; Kim Robien; V Wendy Setiawan; Anthony Swerdlow; Piet A van den Brandt; Elisabete Weiderpass; Lynne R Wilkens; Alicja Wolk; Nicolas Wentzensen; Shelley S Tworoger Journal: J Natl Cancer Inst Date: 2019-02-01 Impact factor: 13.506
Authors: Britton Trabert; Roberta B Ness; Wei-Hsuan Lo-Ciganic; Megan A Murphy; Ellen L Goode; Elizabeth M Poole; Louise A Brinton; Penelope M Webb; Christina M Nagle; Susan J Jordan; Harvey A Risch; Mary Anne Rossing; Jennifer A Doherty; Marc T Goodman; Galina Lurie; Susanne K Kjær; Estrid Hogdall; Allan Jensen; Daniel W Cramer; Kathryn L Terry; Allison Vitonis; Elisa V Bandera; Sara Olson; Melony G King; Urmila Chandran; Hoda Anton-Culver; Argyrios Ziogas; Usha Menon; Simon A Gayther; Susan J Ramus; Aleksandra Gentry-Maharaj; Anna H Wu; Celeste Leigh Pearce; Malcolm C Pike; Andrew Berchuck; Joellen M Schildkraut; Nicolas Wentzensen Journal: J Natl Cancer Inst Date: 2014-02 Impact factor: 11.816
Authors: Kamisha T Woolery; Mai Mohamed; Rebecca J Linger; Kimberly P Dobrinski; Jesse Roman; Patricia A Kruk Journal: Biomed Res Int Date: 2015-08-19 Impact factor: 3.411